clinical trial · NCT06051617
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Gilead Sciences·phase3·recruiting·n = 318
Primary Biliary CholangitisSeladelparPlacebo
brief summary
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
started
Sep 7, 2023
primary completion
Aug 1, 2030
completion
Aug 1, 2030
last updated
Apr 1, 2026
detailed description
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
official title
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol